Tiropramide

Summary

Tiropramide (CHEMBL2104688) is a phase-3 clinical-stage small molecule (ATC A03AC05); indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A03AC05
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 467.6 Da · C28H41N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104688
Name	Tiropramide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	42262
ATC	A03AC05
Molecular formula	C28H41N3O3
Molecular weight	467.6
InChIKey	FDBWMYOFXWMGEY-UHFFFAOYSA-N

SMILES: CCCN(CCC)C(=O)C(CC1=CC=C(C=C1)OCCN(CC)CC)NC(=O)C2=CC=CC=C2

IUPAC name: N-[3-[4-[2-(diethylamino)ethoxy]phenyl]-1-(dipropylamino)-1-oxopropan-2-yl]benzamide

Also known as: Tiropramida, Tiropramide, TIROPRAMIDE

Patent coverage: 294 distinct patent families (1,179 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01629212	PHASE4	UNKNOWN	Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).